The Role of Dermcidin Isoform 2: A Two-Faceted Atherosclerotic Risk Factor for Coronary Artery Disease and the Effect of Acetyl Salicylic Acid on It

<table>Aggregation of platelets by ADP and dermcidin and the aggregation of platelets in the presence of both ADP and dermcidin added to PRP. Platelet-rich plasma was prepared from the blood of normal volunteers, and the aggregation of platelet was determined by treating the PRP with either ADP (4 <i>μ</i>M) or dermcidin (0.1 <i>μ</i>M) or with both ADP and dermcidin. The curve A: aggregation of platelets when both ADP and dermcidin were added to the PRP. Curve B: dermcidin-induced platelet aggregation. Curve C: ADP-induced platelet aggregation. Curve D: aspirin-(80 <i>μ</i>M) induced inhibition of platelet aggregation induced by dermcidin. The figure represents a typical platelet aggregation in the presence of ADP, dermcidin, or both ADP and dermcidin from 6 different experiments using blood samples from 6 different normal volunteers.</table>

Thrombosis

fig4

Figure 4

Figure 4: The Role of Dermcidin Isoform 2: A Two-Faceted Atherosclerotic Risk Factor for Coronary Artery Disease and the Effect of Acetyl Salicylic Acid on It 

Figure 4 | The Role of Dermcidin Isoform 2: A Two-Faceted Atherosclerotic Risk Factor for Coronary Artery Disease and the Effect of Acetyl Salicylic Acid on It 